Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective

BACKGROUND: U.S. regulatory approvals of the cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors ribociclib and palbociclib as add-ons to letrozole greatly enhance the prospects for treating postmenopausal women with hormone receptor-positive (HR+)/human epidermal receptor 2-negative (HER2-) advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Mistry, Rohit, May, Jessica R., Suri, Gaurav, Young, Kate, Brixner, Diana, Oderda, Gary, Biskupiak, Joseph, Tang, Derek, Bhattacharyya, Subrata, Mishra, Dinesh, Bhattacharyya, Devarshi, Dalal, Anand A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398120/
https://www.ncbi.nlm.nih.gov/pubmed/29799329
http://dx.doi.org/10.18553/jmcp.2018.24.6.514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398120/
https://www.ncbi.nlm.nih.gov/pubmed/29799329
http://dx.doi.org/10.18553/jmcp.2018.24.6.514

Ejemplares similares